Media coverage about NeuroDerm (NASDAQ:NDRM) has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NeuroDerm earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.2443080338435 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several research analysts have recently commented on the company. Raymond James Financial, Inc. downgraded NeuroDerm from an “outperform” rating to a “market perform” rating and set a $39.00 target price on the stock. in a report on Monday, July 24th. Zacks Investment Research downgraded NeuroDerm from a “hold” rating to a “sell” rating in a report on Thursday. Roth Capital downgraded NeuroDerm from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $33.00 to $39.00 in a report on Wednesday, August 2nd. BidaskClub raised NeuroDerm from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of NeuroDerm in a report on Sunday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $44.13.

NeuroDerm (NASDAQ NDRM) opened at 38.60 on Friday. The firm’s market cap is $1.02 billion. The stock has a 50 day moving average price of $33.65 and a 200-day moving average price of $27.49. NeuroDerm has a 1-year low of $15.20 and a 1-year high of $38.85.

NeuroDerm (NASDAQ:NDRM) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.13. Equities research analysts forecast that NeuroDerm will post ($2.03) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at

About NeuroDerm

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

Insider Buying and Selling by Quarter for NeuroDerm (NASDAQ:NDRM)

Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.